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ABSTRACT
Tuna cooking juice containing 4% protein was hydrolyzed using a commercial protease, Orientase from Bacillus subtilis, to
prepare hydrolysate (OAH) that inhibits angiotensin I-converting enzyme (ACE). The systolic blood pressure (SBP) dropped by
18 mmHg in spontaneously hypertensive rats (SHR) 2hr after being orally administered the hydrolysate at 0.25g hydrolysate/kg
body weight, and reduced, from 172 mmHg to 150 and 142 mmHg for those administered with lyophilized OAH at 0.5 and 1.0 g/kg
body weight, respectively. This indicated that the lowering effect on SBP was dose-dependent. Constituents derived from the gel
filtration of OAH with molecular weight ranging from 240-565 Da exerted an obvious effect on SBP. Although the reduced SBP
in SHR gradually returned to the original level, the reduction effect lasted for 2-10 hr, depending on the dose. The SBP of SHR
fed on a normal diet increased gradually to 215 mmHg by the age of 15 weeks, while it decreased, then increased to and stayed at,
respectively, 200, 205 and 215 mmHg for those fed on diets containing 2.5, 1.25 or 0.25% lyophilized OAH. This result showed that
proteins in tuna cooking juice are potential source of ACE-inhibiting agent, and thus may be useful to regulate the blood pressure.
Key words: tuna cooking juice, hydrolysates, anti-hypertensive properties, angiotensin I-converting enzyme (ACE)

INTRODUCTION
The angiotensin I-converting enzyme (ACE) catalyzes the formation of angiotensin II, a strong vasopressor from angiotensin I, and inactivates bradykinin, which
exhibits hypotensive activity(1). ACE inhibitors, such as
the commercially anti-hypertensive drugs captopril and
enalapril, block both of these actions, thus contributing
to their potent anti-hypertensive activities in spontaneously hypertensive rats (SHR) or patients (2). Recently,
various peptides or hydrolysates derived from food
proteins were found to inhibit ACE (3-8). Many studies
also demonstrated ACE inhibitors derived from tuna (9-11).
Some of these ACE-inhibiting substances, while given
orally, did reduce the blood pressure in humans and
SHR(1,7,8,12). These findings suggest that those substances are absorbed through the digestive tract, inhibit ACE
activity and subsequently reduce the blood pressure.
Tu na cook i ng ju ice, a prot ei n-r ich by product
containing 4% water-soluble protein, is discarded as
drainage in commercial canned tuna factories (13). It is
essential to recover the proteins in order to prevent water
pollution and to achieve complete utilization of available
proteins. Our previous study indicated that orientase, a
commercial protease from Bacillus subtillu, effectively
* Author for correspondence. Tel: +886-4-26318652 ext. 5000;
Fax: +886-4-24735325; E-mail: jyhsheng@sunrise.hk.edu.tw

released ACE- inhibitory peptides and the absorptionenhancing treatments increased the antihypertensive
activity of these peptides from tuna cooking juice in
vivo in SHR (14,15). In this report, the inhibitory effect
of orientase hydrolysate (OAH) and its fractions on the
development of hypertension in SHR during oral administration were investigated in the hope that the development of foods for blood pressure control could benefit.

MATERIALS AND METHODS
I. Materials and Reagents
Tuna cooking juice containing 4% proteins was
obtained from a tuna can plant in Chiayi County, Taiwan.
Captopril was purchased from Sigma Chemicals (MO,
USA). Orientase, an endopeptidase prepared from Bacillus subtilis, was purchased from Hankyu Bioindustry Co.
(Osaka, Japan). All other chemicals were of analytical
grade.
II. Preparation of Tuna Cooking Juice Hydrolysate
Orientase (1.0%, w/w) was added to the tuna cooking juice in a ratio of substrate/enzyme = 25 (v/v), i.e.
E/S = 1/250. Enzymatic hydrolysis was performed at
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50°C for 3 hr. The juice was then boiled for 10 min to
inactivate the protease. The reaction mixture was centrifuged at 10,000 ×g for 10 min, and the supernatant was
collected and lyophilized as OAH.
III. Fractionation of OAH
OAH (280 mg) dissolved in 1 mL of distilled water
was applied on a Sephadex G-25 column (2.5 × 70 cm)
The elution was effected with 0.05 M phosphate buffer
(pH 6.5) at a f low rate of 45 mL/hr. The eluent was
collected in the 5 mL of fraction. The absorbance at 280
nm and the ACE inhibitory activity of all fractions were
measured. The distribution of molecular weight (MW) of
hydrolysate was estimated using β-endothein (MW 2,573),
neurotensin (MW 1,672.9), bradykinin (MW 1,060), [Sar1,
Ala8] angiotensin-II (MW 926), N-formyl-Met-Leu-PheLys (MW 565.7) and tryptophan (MW 204).
IV. Single Oral Administration in SHR
Eig ht-week- old male SH R s obt ai ned f rom t he
National Laboratory Animal Breeding and Research
Center (Taipei, Taiwan, ROC) were fed on autoclavable
rodent diet (Labdie Co., USA) consisting of 55.5% carbohydrates, 23% protein, 4.5% fat, 6.0% fiber and 3.0%
minerals, and were given water ad libitum. All rats were
housed for 7 days to help them acclimatize to their new
environment. After being housed in cages controlled at
22 ± 3°C, RH 50 ± 10%, and 12 hr light/12 hr dark (lights
on 06:00 hr), the rats were randomly given 0.25, 0.5 or
1.0 g/kg of body weight of OAH or its fractions from gel
filtration in saline by gastric incubation (8 rats/group).
Control group rats were administered the same amount
of saline. Systolic blood pressure (SBP) was measured 0,
2, 4, 6, 8 and 10 hr thereafter. Long-term oral administration for SHR was as follows: commercial diets mixed
with 0.25, 1.25 or 2.50% (w/w) lyophilized OAH were
fed to SHR from age 9 weeks to age 17 weeks. The SBP
of SHR was measured once a week.
V. Characterization of the Inhibition of ACE
ACE inhibitory activity was measured spectrophotometrically using hippuryl-L-histidyl-L-leucine (HipHis-Leu) as substrate, as described by Cushman and
Cheung(16). Fifty microliter of sample solution and 100 µL
of 2.5 mU ACE solution were added to 100 µL of 12.5 mM
Hip-His-Leu solution in 1.0 M NaCl-borate, pH 8.3. After
incubation at 37°C for 1 hr, the reaction was stopped by
adding 250 µL of 0.5 N HCl. The liberated hippuric acid
was extracted with 1.5 mL of ethyl acetate, and the absorbance at 228 nm was measured to determine the ACE
inhibitory activity. The inhibition rate (%) is expressed as
{(Ec-Es)/(Ec-Eb)} × 100, where Es is the absorbance when
the sample is added to the reaction mixture; Ec is the
absorbance with buffer (instead of the sample) added, and

Eb is the absorbance where the stop solution was added
before the reaction started. The IC50 value is the sample
concentration associated with 50% inhibition on ACE.
VI. Measurement of Blood Pressure
The systolic blood pressures (SBP) of five rats were
measured by the tail-cuff method using an indirect blood
pressure meter (BP-98A, Softron Co. Ltd., Japan). The
rats were warmed in a 39-40°C box for 10 min before their
blood pressure was measured. Five readings were recorded and the average SBP calculated. The significance of
the differences between the SBP before and after the OAH
administration was analyzed using the paired t-test.

RESULTS AND DISCUSSION
I. ACE Inhibitory Action from OAH
Intact tuna cooking juice or its protein fraction did
not suppress the action of ACE. However, the hydrolysate by a commercial protease, Orientase from Bacillus subtilis, inhibited ACE, and the IC50 was 5.85 mg
protein/mL (Table 1). The IC50 value of OAH was slightly
higher than that of sardine muscle hydrolysate (3.15 mg
protein /mL)(17). Inhibition of ACE activity results in the
decrease of blood pressure. Pharmatherapeutic efforts
to reduce the increase in blood pressure in hypertensives
have been undertaken by suppressing the production of
active angiotensin II precursor, or by inhibiting the catalytic activity of ACE (18). The intake of sardine muscle
hydrolysate and casein hydrolysate for a 4-week protocol
could induce potent anti-hypertensive effects in mild
hypertensives(3,19,20). Thus, the intake of protein hydrolysate OAH with ACE inhibitory activity seems to be of
great potential for regulating blood pressure.
II. Anti-hypertensive Activity of OAH in SHR
Rats, age of 9 weeks, were given 0.25 g OAH per
kg of body weight by gastric incubation. The mean SBP

Table 1. Change in inhibition of ACE in tuna cooking juice samples
following various treatments
IC50 value

Treatment

(mg/mL)

(mg protein/mL)

Intact (tuna cooking juice)

NI

NI

TCA

NI

NI

46.89

5.85

Orientase hydrolysis &
lyophilization

Intact tuna cooking juice was hydrolyzed with 0.4 weight % of
orientase for 3 hr, and subsequently lyophilized. Trichloroacetic
acid (TCA, 10%) treatment was performed to determine the protein
fraction of the tuna cooking juice. NI: no inhibition.
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was 172 ± 3.5 mmHg before OAH administration and was
considerably reduced by 18 ± 2 mmHg 2 hr after administration (Figure 1). SBP then returned to the initial level at
4 hr after administration. In contrast, the SBP of rats who
had been given saline or tuna cooking juice did not change
significantly during the period of 24 hr. Also as shown in
Figure 1, OAH significantly lowered SBP in SHR between
2 hr and 4 hr after 0.5g OAH /kg body weight was orally
administered. A higher dose (1.0 g/kg body weight) was
resulted in a stronger anti-hypertensive effect and a reduction in SBP by 30 mmHg 2 hr after administration was
observed; this effect was maintained for 8 hr. OAH (0.25,
0.5, 1.0 g/kg body weight) yielded, in a dose-dependent
manner, a lower blood pressure than control (saline) did.
This study demonstrated for the first time that a
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Figure 1. Changes in SBP after single oral administration of
tuna cooking juice hydrolysate or Captopril (10 mg/kg) to SHR.
*Outcomes were significantly different from those of controls; p <
0.05.
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Figure 2. Changes in SBP after single oral administration of tuna
cooking juice hydrolysate fractionated by gel filtration to SHR.
*Outcomes were significantly different from those of controls; p <
0.05.

single oral administration of the ACE-inhibiting hydrolysate from tuna cooking juice could persistently lower,
but did not normalize, the SBP in SHR. This finding is
similar to that obtained in other studies on SHR treated
with several other ACE-inhibiting hydrolysates (21,22).
In the present study, tuna cooking juice did not lower
the blood pressure in SHR at all. However, protelyotic hydrolysis by orientase resulted in a boost of antihypertensive effect. OAH exhibited a more potent antihypertensive effect (1 g/kg dose lowered SBP by 30 ±
2.7 mmHg after 2hr) than the royal protein hydrolysate
(1g/kg dose lowered SBP by 22 ± 3.6 mmHg after 2hr)
or α-zein hydrolysate (2 g/kg dose lowered SBP by 25
mmHg after 3 hr) did (23,24) . Hydrolysed proteins in
tuna cooking juice might thus server as a good source of
inhibitors of ACE for regulating blood pressure.
In order to compare the anti-hypertensive activity of OAH with commercial drugs, Captopril was used
as a reference drug for the reducing the SBP on SHR.
As shown in Figure 1, SBP significantly dropped in
the period of 2 to 8 hr after Captopril (10 mg/kg body
weight) was orally administered. Captopril was clearly
show n to affect the hy per tension rapidly and for a
prolonged period. Obviously, OAH did not lower blood
pressure as readily as Captopril. Nevertheless, Captopril
does not negate the application of cooking juice hydrolysates in preventing hypertension. OAH, unlike Captopril, is expected to have no undesirable side effects.
III. Anti-hypertensive Activity of Fractions from OAH in
SHR
Gel filtration was used to fractionate the OAH. The
changes in SBP for 24 hr after the administration of various fractions of OAH to SHR were shown in Figure 2.
Of these fractions, OA3 inhibited ACE most remarkably
reducing the blood pressure by 25 ± 2.7 mmHg when
orally administered 0.5 g/kg body weight. Reduction
effect lasted for 8 hr, though the reduced SBP gradually
returned to the initial level. The next strongest inhibitor
was the OA4 fraction, which reduced blood pressure by
12 ± 2.2 mmHg in SHR 2 hr after orally administered 0.5
g/kg body weight. In contrast, the SBP of rats given 0.5
g/kg body weight of OA2 fraction reduced only slightly;
it did not change significantly over the 24 hr period of
observation. The rats administered the OA1 fraction
were similar to the control group. Higher doses of OA3
and OA4 fractions (1.0 g/kg) reduced SBP by 35 mmHg
and 26 mmHg, respectively as compared to the control.
The reduction effect from OA4 held only for 10 hr; on
the other hand, that from OA3 lasted for more than 10
hr. The results indicate that OA3 and OA4 fractions had
stronger and lasting effects on the blood pressure of SHR.
From our previous study (14) , OA3 and OA4 with MW
ranging from 0.204 to 1.06 kDa, exhibited ACE-inhibiting effect with IC50 value of 0.21 mg and 0.52 mg protein/
mL, respectively. On the contrary, OA1 (MW > 2573)
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and OA2 (926 > MW > 565) had no effect on ACE. Inhibition of ACE activity shall results the lowering of blood
pressure. Fractioned OAH exerted an anti-hypertensive
effect by inhibiting the ACE activity. Moreover, fragments generated herein were composed of peptides from
0.204 to 1.06 kDa, which were responsible for lowering
the blood pressure. This finding was consistent with
that of another report on anti-hypertensive peptides with
small MW (usually 2 to 14 amino acids residues)(25).
IV. Effect of Long Term Feeding on Hypertension
The long term effects during eight weeks of treatment on a diet that including OAH were illustrated in
Figure 3. The standard commercial diets were minced
with 0.25%, 1.25% or 2.5% (w/w) OAH. The SHR were
first fed the hydrolysate-containing diet at age of 9 weeks.
The SBP in all the control rats gradually elevated in the
course of the experiment, reaching about 216 ± 3.2 mmHg
at age of 17 weeks. At age of 12 weeks, the SBP of rats
fed a OAH-containing diet tended to be lower, in a dosedependent manner, than that of the control group. When
the rats were 15 weeks old, SBP was significantly lower in
the 2.50% (w/w) OAH group than that in the control group.
At the eighth week, the blood pressures were, respectively,
3.2% and 6.5 % lower in the groups to which the OAH 1.25
and 2.5% had been administered than those in the control
group. The level of SBP typically dropped from the third
week of the experiment in OAH-fed rats rather than the
controls. The increases in blood pressures were reduced in
a dose-dependent manner from the sixth to eighth weeks of
the experiment. Moreover, SBP of SHR fed diets containing 2.5, 1.25 and 0.25% OAH dropped, then increased to
and stayed at 200, 205 and 215 mmHg, respectively. These
findings imply that OAH participates in suppressing or
delaying the development of hypertension.
However, the SBP value were higher in the OAH
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Figure 3. Changes in SBP of SHR fed on a diet that includes tuna
cooking juice hydrolysate. *Outcomes were significantly different
from those of controls; p < 0.05.

groups than in the normotensive rats reported in earlier
studies, 200 mmHg at 17 weeks old in the group at the
highest dose administered herein versus 150 mmHg in the
normotensive rats, according to Rizzoni et al.(26). This
finding indicates that OAH can moderately suppress the
increase of blood pressure though the SBP in SHR will
continue to increase until 20 weeks old. This characteristic
of OAH is potentially important in its use as a physiologically functional food since excessive reduction in blood
pressure has been shown to induce myocardial infarction
and to affect survival rate(27-29). These results indicate that
OAH may be useful in regulating blood pressure.

CONCLUSIONS
In conclusion, hydrolysate and its fractions obtained
by hydrolyzing the tuna cooking juice have been shown
inhibit ACE action in vitro and to exert anti-hypertensive effect by oral administration. They actually prevent
the development of hypertension in SHR. These results
suggest that the increase in blood pressure can be partially inhibited by taking hydrolysate derived from the tuna
cooking juice. Finally, such hydrolysates containing
oligopeptides are expected to be usable in food to control
the blood pressure in patients with essential hypertension. However, further studies should be undertaken to
examine the amino acid sequences, active mechanisms,
and the side effects of using hydrolysates.
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